Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randy Miller

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|May 2, 2021
Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug developmentPaul van den Berg, Wei Gao, Maurice J Ahsman, et al.
Hemoglobin|December 10, 2008
Neonatal cyanosis due to a novel fetal hemoglobin: Hb F-Circleville [Ggamma63(E7)His-->Leu, CAT>CTT]Erin Dainer, Richard Shell, Randy Miller, et al.
Plastic and Reconstructive Surgery|August 29, 2002
Radiotherapy: effects on expanded skinCynthia M Goodman, Randy Miller, Charles W Patrick, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Design and Synthesis of P2-P4 Macrocycles Containing a Unique Spirocyclic Proline: A New Class of HCV NS3/4A InhibitorsFrancisco Velázquez, Mariappan Chelliah, Martin Clasby, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of ObesityIyassu K Sebhat, Christopher Franklin, Michael M-C Lo, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of ObesityHarry R Chobanian, Yan Guo, Ping Liu, et al.
Bioorganic & Medicinal Chemistry|April 13, 2012
The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerizationHarry R Chobanian, Yan Guo, Ping Liu, et al.
Cell Metabolism|January 26, 2010
Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesityXiao-Ming Guan, Howard Chen, Peter H Dobbelaar, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chiralityPing Liu, Thomas J Lanza, Marc Chioda, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease InhibitorSanthosh F Neelamkavil, Sony Agrawal, Thomas Bara, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|May 2, 2021
Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug developmentPaul van den Berg, Wei Gao, Maurice J Ahsman, et al.
Hemoglobin|December 10, 2008
Neonatal cyanosis due to a novel fetal hemoglobin: Hb F-Circleville [Ggamma63(E7)His-->Leu, CAT>CTT]Erin Dainer, Richard Shell, Randy Miller, et al.
Plastic and Reconstructive Surgery|August 29, 2002
Radiotherapy: effects on expanded skinCynthia M Goodman, Randy Miller, Charles W Patrick, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Design and Synthesis of P2-P4 Macrocycles Containing a Unique Spirocyclic Proline: A New Class of HCV NS3/4A InhibitorsFrancisco Velázquez, Mariappan Chelliah, Martin Clasby, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of ObesityIyassu K Sebhat, Christopher Franklin, Michael M-C Lo, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of ObesityHarry R Chobanian, Yan Guo, Ping Liu, et al.
Bioorganic & Medicinal Chemistry|April 13, 2012
The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerizationHarry R Chobanian, Yan Guo, Ping Liu, et al.
Cell Metabolism|January 26, 2010
Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesityXiao-Ming Guan, Howard Chen, Peter H Dobbelaar, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chiralityPing Liu, Thomas J Lanza, Marc Chioda, et al.
ACS Medicinal Chemistry Letters|January 29, 2016
Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease InhibitorSanthosh F Neelamkavil, Sony Agrawal, Thomas Bara, et al.
Pageof 1